AbbVie (ABBV) News Today

AbbVie Inc. (NYSE:ABBV) shares have risen today following a string of positive clinical updates, regulatory approvals, strategic acquisitions and favorable competitive dynamics that bolster its pipeline and growth outlook.

• Positive Sentiment: Health Canada granted a Notice of Compliance (NOC) to AbbVie’s upadacitinib for the treatment of giant cell arteritis, expanding its label and market reach in Canada. Health Canada issues NOC to AbbVie’s upadacitinib for giant cell arteritis
• Positive Sentiment: AbbVie agreed to acquire depression drug candidate bretisilocin for $1.2 billion, enhancing its psychiatric portfolio and long-term revenue potential. AbbVie to acquire depression drug for $1.2B
• Positive Sentiment: In its latest quarterly report, AbbVie beat EPS estimates despite a revenue miss, and highlighted strong progress on bretisilocin—underscoring confidence in its pipeline. AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
• Positive Sentiment: AbbVie reported promising Phase 2/3 data for its NSCLC (non–small cell lung cancer) therapy, raising hopes for a near-term launch in a high-value oncology segment. AbbVie’s Promising Study on NSCLC Treatment: A Potential Game Changer
• Positive Sentiment: Early Phase 2 results for telisotuzumab vedotin in NSCLC showed strong activity, further diversifying AbbVie’s cancer pipeline. AbbVie’s Promising Phase 2 Study on Telisotuzumab Vedotin for NSCLC
• Positive Sentiment: The Phase 1 ABBV-324 antibody-drug conjugate study showed encouraging safety and preliminary efficacy, signaling a new cancer asset in development. AbbVie’s ABBV-324 Study: A New Hope for Cancer Treatment?
• Positive Sentiment: AbbVie's ABBV-453 trial for multiple myeloma delivered promising early data, potentially adding a novel immunotherapy to its hematology lineup. AbbVie’s Promising Study on ABBV-453 for Multiple Myeloma: A Potential Game-Changer
• Positive Sentiment: Phase 2 data for an ADPKD (polycystic kidney disease) treatment showed favorable outcomes, addressing an unmet need and widening AbbVie’s rare disease reach. AbbVie’s Promising Phase 2 Study on ADPKD Treatment: What Investors Should Know
• Positive Sentiment: A Phase 2 atopic dermatitis trial reported encouraging safety and efficacy, expanding AbbVie’s dermatology leadership beyond Humira and Rinvoq. AbbVie’s Promising Phase 2 Trial for Atopic Dermatitis: What Investors Need to Know
• Positive Sentiment: AbbVie’s pediatric bipolar disorder study demonstrated potential benefit in early data, targeting a high-need psychiatry segment. AbbVie’s Pediatric Bipolar Disorder Study: A Potential Game-Changer?
• Positive Sentiment: Johnson & Johnson halted R&D on a potential Humira rival after trial setbacks, reducing competitive pressure on AbbVie’s top-selling biologic. J&J halts R&D for potential rival to AbbVie’s Humira after trial setback
• Positive Sentiment: Zacks analysts favor AbbVie over Merck for 2025, citing robust Skyrizi and Rinvoq sales plus pipeline gains that support higher earnings estimates. ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
• Positive Sentiment: Partner Plexium, collaborating with AbbVie on targeted protein degraders, raised $60 million in new financing—underscoring external confidence in AbbVie’s R&D alliances. Months after layoffs, AbbVie-partnered protein degrader specialist Plexium raises $60M
• Neutral Sentiment: Zacks notes heightened investor attention on ABBV, suggesting rising interest but no immediate directional catalyst. Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
• Neutral Sentiment: MarketBeat’s screen of biotech stocks highlights AbbVie among names to watch, reflecting sector interest but not conveying a specific near-term driver. Biotech Stocks Worth Watching - August 27th